Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease

Mike M Ruth; Jasper J N Sangen; Lian J Pennings; Jodie A Schildkraut; Wouter Hoefsloot; Cecile Magis-Escurra; Heiman F L Wertheim; Jakko van Ingen

doi:10.1128/AAC.01208-18

Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease

Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01208-18. doi: 10.1128/AAC.01208-18. Print 2018 Oct.

Authors

Mike M Ruth¹, Jasper J N Sangen¹, Lian J Pennings¹, Jodie A Schildkraut¹, Wouter Hoefsloot², Cecile Magis-Escurra², Heiman F L Wertheim¹, Jakko van Ingen³

Affiliations

¹ Department of Medical Microbiology, Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
² Department of Respiratory Diseases-TB Expert Centre Dekkerswald, Radboud University Medical Center, Nijmegen, the Netherlands.
³ Department of Medical Microbiology, Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands Jakko.vaningen@radboudumc.nl.

Abstract

Mycobacterium abscessus causes a difficult-to-treat pulmonary disease (MAb-PD). After initial intravenous treatment, minocycline is recommended in the oral continuation phase of treatment. We determined the MICs, synergy, and time-kill kinetics of minocycline against M. abscessus With MICs of 8 to 512 mg/liter, rapid emergence of tolerance in time-kill assays, and no synergy with other drugs used to treat MAb-PD, minocycline appears ineffective against M. abscessus These in vitro data question its role as a MAb-PD treatment modality.

Keywords: Mycobacterium abscessus; minocycline; pharmacokinetics.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Lung Diseases / microbiology
Microbial Sensitivity Tests
Minocycline / pharmacology*
Mycobacterium abscessus / drug effects*

Substances

Anti-Bacterial Agents
Minocycline